[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:peritoneal-neoplasm":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":22,"states":23},"Peritoneal Neoplasm",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07213804","A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer",[11],"Phase 3","RECRUITING","2026-08-26T02:17:27.435233Z","2026-07-05T05:32:16.660912Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06906341","Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers",[19],"Phase 2","2026-08-26T02:17:13.277148Z","2026-05-05T02:43:26.693680Z",[],[]]